Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

Sponsor
Novo Nordisk A/S
Study ID
NCT02773355
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide 3.0 mg — DRUG
    Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.

Study Details

This trial is conducted in North America. The aim is to investigate timely detection of pancreatitis cases as well as cases of suspicion of serious and non-serious adverse reactions possibly or probably related to Saxenda® in Mexican patients.

Key Dates

Start date
May 16, 2016
Status verified
Apr 2026
Primary completion
Nov 30, 2021
Completion
Feb 28, 2022

Study Design

Enrollment
27 participants (actual)

Arms

  • Arm: Saxenda®

Primary Outcome Measure

Frequency of pancreatitis [ Time Frame: Year 0-3 ]

Related Studies